Core Viewpoint - JD Health (06618) has seen a significant increase in stock price, rising nearly 4% in early trading, attributed to the surge in demand for respiratory disease testing kits amid the flu season [1] Group 1: Stock Performance - JD Health's stock price increased by 3.19%, reaching HKD 63, with a trading volume of HKD 149 million [1] Group 2: Market Demand and Response - The demand for flu testing kits has surged, leading JD Health to implement a special supply guarantee mechanism in collaboration with brand partners to ensure stable supply without price increases [1] - JD Health's medical device department formed an IVD brand alliance with multiple brands and companies to anticipate demand and manage inventory effectively [1] Group 3: Product Launch and Innovation - JD Health has launched an exclusive product, Oseltamivir granules (15mg×18 bags), specifically designed for children's flu treatment, addressing issues of dosage mismatch and medication waste [1] - The new product is designed for a 5-day standard treatment course, simplifying the medication process for parents and significantly reducing drug waste [1] - Since its launch, the product has seen an average daily sales growth of over 100%, becoming a preferred choice for families preparing for flu season [1]

京东健康(06618)早盘涨近4%，截至发稿，涨3.19%，报63港元，成交额1.49亿港元。 另一方面，京东健康近期全网独家首发可威奥司他韦颗粒15mg×18袋疗程装，精准聚焦儿童流感治疗 中"剂量不匹配、药品易浪费"的痛点。该规格基于5天标准疗程设计，可覆盖1岁以上、体重低于15kg儿 童的全周期用药，实现"一次购药、覆盖全疗程"，极大简化了家长的备药与用药流程，有效避免药品浪 费。首发以来，该产品日均成交额增速超100%，成为众多家庭流感备药的首选。 消息面上，近日，据动脉网报道，随着各地流感高峰到来，呼吸道传染病检测需求攀升，京东健康数据 显示流感检测试剂盒销量大增，多联检试剂盒成新趋势。为应对需求，京东健康联合品牌商家启动专项 保障机制，确保稳定供应不涨价。其医疗器械部门上月联合多家品牌及企业成立IVD品牌联盟，提前预 测需求，科学备货。同时，京东健康升级履约时效，部分地区最快半小时送达。 ...